COPD [chronic obstructive pulmonary disease] Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole).

Trial Profile

COPD [chronic obstructive pulmonary disease] Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Esomeprazole; Lansoprazole
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Jul 2012 Primary endpoint added as reported by ClinicalTrials.gov.
    • 23 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top